α-2,3-Sialyltransferase Expression Level Impacts the Kinetics of Lipooligosaccharide Sialylation, Complement Resistance, and the Ability of Neisseria gonorrhoeae to Colonize the Murine Genital Tract
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Neisseria meningitidis and Neisseria gonorrhoeae modify the terminal lacto- N -neotetraose moiety of their lipooligosaccharide (LOS) with sialic acid. N. gonorrhoeae LOS sialylation blocks killing by complement, which is mediated at least in part by enhanced binding of the complement inhibitor factor H (FH). The role of LOS sialylation in resistance of N. meningitidis to serum killing is less well defined. Sialylation in each species is catalyzed by the enzyme LOS α-2,3-sialyltransferase (Lst). Previous studies have shown increased Lst activity in N. gonorrhoeae compared to N. meningitidis due to an ~5-fold increase in lst transcription. Using isogenic N. gonorrhoeae strains engineered to express gonococcal lst from either the N. gonorrhoeae or N. meningitidis lst promoter, we show that decreased expression of lst (driven by the N. meningitidis promoter) reduced LOS sialylation as determined by less incorporation of tritium-labeled cytidine monophospho- N -acetylneuraminic acid (CMP-NANA; the donor molecule for sialic acid). Diminished LOS sialylation resulted in reduced rates of FH binding and increased pathway activation compared to N. gonorrhoeae promoter-driven lst expression. The N. meningitidis lst promoter generated sufficient Lst to sialylate N. gonorrhoeae LOS in vivo , and the level of sialylation after 24 h in the mouse genital tract was sufficient to mediate resistance to human serum ex vivo . Despite demonstrable LOS sialylation in vivo , gonococci harboring the N. meningitidis lst promoter were outcompeted by those with the N. gonorrhoeae lst promoter during coinfection of the vaginal tract of estradiol-treated mice. These data highlight the importance of high lst expression levels for gonococcal pathogenesis. IMPORTANCE Neisseria gonorrhoeae has become resistant to nearly every therapeutic antibiotic used and is listed as an “urgent threat” by the Centers for Disease Control and Prevention. Novel therapies are needed to combat drug-resistant N. gonorrhoeae. Gonococci express an α-2,3-sialyltransferase (Lst) that can scavenge sialic acid from the host and use it to modify lipooligosaccharide (LOS). Sialylation of gonococcal LOS converts serum-sensitive strains to serum resistance, decreases antibody binding, and combats killing by neutrophils and antimicrobial peptides. Mutant N. gonorrhoeae that lack Lst (cannot sialylate LOS) are attenuated in a mouse model. Lst expression levels differ among N. gonorrhoeae strains, and N. gonorrhoeae typically expresses more Lst than Neisseria meningitidis . Here we examined the significance of differential lst expression levels and determined that the level of LOS sialylation is critical to the ability of N. gonorrhoeae to combat the immune system and survive in an animal model. LOS sialylation may be an ideal target for novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![FIG 1 Incorporation of CMP-NANA onto LNT-LOS by Lst and the relationship of sialylation kinetics to binding of FH and MAb 3F11. (A) Incorporation of CMP-NANA by N. gonorrhoeae F62ΔD expressing lst either from its native promoter (Ng Plst-Ng) or from the N. meningitidis 126E lst promoter (Ng Plst-Nm) and N. meningitidis NMB SiaA (Nm NMB SiaA). Strains were grown in the presence of 2 µg/ml CMP-NANA (50:1 [wt/wt] unlabeled CMP-NANA/labeled CMP sialic acid [sialic-6-3H]), and incorporation was measured over time. Negative controls included N. gonorrhoeae Δlst lacking the sialyltransferase enzyme, Lst (Ng Δlst), and N. gonorrhoeae Plst-Ng grown in the absence of CMP-NANA [Ng Plst-Ng (No CMP-NANA)]. Values are the means and standard deviations of the results of triplicate measurements from three independent experiments. (B) Kinetics of FH binding in relation to LOS sialylation. Flow cytometry was used to measure binding of human FH (10 µg/ml) and MAb 3F11 (recognizes the unsialylated LNT-LOS epitope) to N. gonorrhoeae F62ΔD over time following the addition of CMP-NANA (2 µg/ml) to log-phase cultures. Bound human FH was detected with MAb 90X, and sialylation of the LNT LOS epitope was detected by loss of reactivity with MAb 3F11. The x axis represents time in minutes, and the y axis represents the median fluorescence. The analysis was conducted three times, and results from a representative experiment are shown.](https://figures.cochat.ai/paper-figures/144ae0a392cb4dde96800b43a6694573/2-3-sialyltransferase-expression-level-impacts-the-kinetics-of-figure-1.jpg)
![FIG 2 FH binding to N. gonorrhoeae correlates with lst expression level. Binding of FH to N. gonorrhoeae F62ΔD expressing the F62 Lst amino acid sequence driven by either the F62 lst promoter (Plst-Ng) or the N. meningitidis 126E lst promoter (Plst-Nm) (A and B) or binding of FH to strain F62ΔD expressing either the N. gonorrhoeae Lst or the N. meningitidis Lst amino acid sequence (C) was measured by FACS analysis using human FH and affinity-purified polyclonal goat anti-human FH. Binding was measured over time (0 to 30 min as indicated) following the addition of CMP-NANA (0.5 µg/ml) to bacteria. Control reactions included (i) bacteria incubated with high concentrations of CMP-NANA (25 mg/ml) for 30 min, (ii) bacteria incubated without CMP-NANA, and (iii) bacteria that were not incubated with FH. An lst mutant (Δlst) also served as a negative control (data not shown). (A) Histograms from a representative experiment comparing Plst-Ng (grey shaded) and Plst-Nm (bold black line) are shown. The y axis represents the number of events (counts), and the x axis represents fluorescence on a log10 scale. FH was omitted in the negative control (thin black line). Numbers alongside the histograms (e.g., the shaded box corresponds to the shaded histograms) are the median fluorescence values. Results showing binding of FH to both strains following incubation with 25 µg/ml CMP-NANA for 30 min are shown (lower left histograms). (B) Median fluorescence with standard errors of the means (SEM) of the results from 6 independent experiments comparing FH binding to Plst-Ng (grey bars) and Plst-Nm (black bars) are shown on the y axis. Each bar represents the mean of the median fluorescence values. *, P < 0.05; **, P < 0.01; ***, P < 0.0001 (Bonferroni’s posttest 2-way analysis of variance [ANOVA]). (C) Median fluorescence values with SEM from 5 independent experiments comparing levels of FH binding to strain F62ΔD expressing either the N. gonorrhoeae Lst (LstNg) or N. meningitidis Lst (LstNm) amino acid sequence are shown on the y axis. Each bar represents the mean of the median fluorescence values. ns, not significant (P > 0.05; Bonferroni’s posttest 2-way ANOVA).](https://figures.cochat.ai/paper-figures/7dc6a95077f94f2b8155b85034b7d64a/2-3-sialyltransferase-expression-level-impacts-the-kinetics-of-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent work (157, 966 -968) has also af fi rmed prior evidence that sialoglycan recognition by factor H can blunt immune responses by inhibiting the alternate pathway of complement activation (966, 969).”
From Biological roles of glycans (2017) · cites this paper as [967]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement control protein factor H: The good, the bad, and the inadequate
Ferreira, V. P., Pangburn, M. K., & Cortés, C. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.05.007 · Cited by 420
Ram, S., Sharma, A. K., Simpson, S. D., Gulati, S., McQuillen, D. P., Pangburn, M. K., & Rice, P. A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.5.743 · Cited by 398
Self-citationShafer, W. M., Qu, X.-D., Waring, A. J., & Lehrer, R. I. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1829 · Cited by 391
Madico, G., Welsch, J. A., Lewis, L. A., McNaughton, A., Perlman, D. H., Costello, C. E., Ngampasutadol, J., Vogel, U., Granoff, D. M., & Ram, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.501 · Cited by 390
Self-citationRam, S., McQuillen, D. P., Gulati, S., Elkins, C., Pangburn, M. K., & Rice, P. A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.4.671 · Cited by 278
Self-citationMeningococcal disease and the complement system
Lewis, L. A., & Ram, S. (2014) · Virulence · doi:10.4161/viru.26515 · Cited by 227
Self-citationUse of mixed infections with strains to study virulence genes and their interactions in vivo
Beuzón, C. R., & Holden, D. W. (2001) · Microbes and Infection · doi:10.1016/s1286-4579(01)01496-4 · Cited by 209
Mehr, I. J., & Seifert, H. S. (1998) · Molecular Microbiology · doi:10.1046/j.1365-2958.1998.01089.x · Cited by 193
Warner, D. M., Shafer, W. M., & Jerse, A. E. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06424.x · Cited by 192
Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation
Jarvis, G. A., & Vedros, N. A. (1987) · Infection and Immunity · doi:10.1128/iai.55.1.174-180.1987 · Cited by 182
Cited by
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“Recent work (157, [966] [967] [968] has also affirmed prior evidence that sialoglycan recognition by factor H can blunt immune responses by inhibiting the alternate pathway of complement activation (966, 969) .”
BackgroundNeisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development
Rice, P. A., Shafer, W. M., Ram, S., & Jerse, A. E. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090816-093530 · Cited by 171
Self-citationIdentification of Allobaculum mucolyticum as a novel human intestinal mucin degrader
van Muijlwijk, G. H., van Mierlo, G., Jansen, P. W. T. C., Vermeulen, M., Bleumink‐Pluym, N. M. C., Palm, N. W., van Putten, J. P. M., & de Zoete, M. R. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1966278 · Cited by 123
Progress Toward a Gonococcal Vaccine: The Way Forward
Russell, M. W., Jerse, A. E., & Gray‐Owen, S. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02417 · Cited by 95
Uchiyama, S., Sun, J., Fukahori, K., Ando, N., Wu, M., Schwarz, F., Siddiqui, S. S., Varki, A., Marth, J. D., & Nizet, V. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815572116 · Cited by 80
Advancement of Sialyltransferase Inhibitors: Therapeutic Challenges and Opportunities
Szabo, R., & Skropeta, D. (2016) · Medicinal Research Reviews · doi:10.1002/med.21407 · Cited by 72
Gulati, S., Schoenhofen, I. C., Whitfield, D. M., Cox, A. D., Li, J., Michael, F. S., VINOGRADOV, E. V., Stupak, J., Zheng, B., Ohnishi, M., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005290 · Cited by 70
Self-citationNeisseria gonorrhoeae vaccines: a contemporary overview
Williams, E., Seib, K. L., Fairley, C. K., Pollock, G. L., Hocking, J. S., McCarthy, J. S., & Williamson, D. A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00094-23 · Cited by 80
Biological feasibility and importance of a gonorrhea vaccine for global public health
Vincent, L. R., & Jerse, A. E. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.081 · Cited by 68
Jennings, M. P., Day, C. J., & Atack, J. M. (2022) · Microbiology · doi:10.1099/mic.0.001157 · Cited by 62
Ram, S., Gulati, S., Lewis, L. A., Chakraborti, S., Zheng, B., DeOliveira, R. B., Reed, G. W., Cox, A. D., Li, J., Michael, F. S., et al. (2018) · Infection and Immunity · doi:10.1128/iai.00285-18 · Cited by 40
Self-citationMatthias, K., Connolly, K. L., Begum, A. A., Jerse, A. E., Macintyre, A. N., Sempowski, G. D., & Bash, M. C. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab450 · Cited by 41
A Novel Factor H–Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae
Shaughnessy, J., Gulati, S., Agarwal, S., Unemo, M., Ohnishi, M., Su, X.-H., Monks, B. G., Visintin, A., Madico, G. E., Lewis, L. A., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1500292 · Cited by 38
Self-citationChakraborti, S., Lewis, L. A., Cox, A. D., Michael, F. S., Li, J., Rice, P. A., & Ram, S. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600374 · Cited by 37
Self-citationEmerging glyco‐based strategies to steer immune responses
Anderluh, M., Berti, F., Bzducha‐Wróbel, A., Chiodo, F., Colombo, C., Compostella, F., Durlik-Popińska, K., Ferhati, X., Holmdahl, R., Jovanović, D. J., et al. (2021) · FEBS Journal · doi:10.1111/febs.15830 · Cited by 39
Ram, S., Shaughnessy, J., DeOliveira, R. B., Lewis, L. A., Gulati, S., & Rice, P. A. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.05.016 · Cited by 35
Self-citationGonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics
Ram, S., Shaughnessy, J., DeOliveira, R. B., Lewis, L. A., Gulati, S., & Rice, P. A. (2017) · Pathogens and Disease · doi:10.1093/femspd/ftx049 · Cited by 32
Self-citationWang, H., Liu, L., Cao, Q., Mao, W., Zhang, Y., Qu, X., Cai, X., Lv, Y., Chen, H., Xu, X., et al. (2018) · Virulence · doi:10.1080/21505594.2018.1502606 · Cited by 25
Lewis, L. A., Rice, P. A., & Ram, S. (2018) · Infection and Immunity · doi:10.1128/iai.00658-18 · Cited by 27
Self-citationHuman Factor H Domains 6 and 7 Fused to IgG1 Fc Are Immunotherapeutic against Neisseria gonorrhoeae
Shaughnessy, J., Lewis, L. A., Zheng, B., Carr, C. R., Bass, I., Gulati, S., DeOliveira, R. B., Gose, S. O., Reed, G. W., Botto, M., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701666 · Cited by 24
Self-citationDiscovery and characterization ofde novosialic acid biosynthesis in the phylumFusobacterium
Lewis, A. L., Robinson, L. S., Agarwal, K., & Lewis, W. G. (2016) · Glycobiology · doi:10.1093/glycob/cww068 · Cited by 23
Biological functions of sialic acid as a component of bacterial endotoxin
Dudek, B., Rybka, J., Bugla‐Płoskońska, G., Korzeniowska‐Kowal, A., Futoma-Kołoch, B., Pawlak, A., & Gamian, A. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1028796 · Cited by 21
Biology of the Gonococcus: Disease and Pathogenesis
Shaughnessy, J., Ram, S., & Rice, P. A. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9496-0_1 · Cited by 27
Self-citationAnti-Virulence Therapeutic Approaches for Neisseria gonorrhoeae
Lim, K. Y. L., Mullally, C. A., Haese, E. C., Kibble, E. A., McCluskey, N. R., Mikucki, E. C., Thai, V. C., Stubbs, K. A., Sarkar‐Tyson, M., & Kahler, C. M. (2021) · Antibiotics · doi:10.3390/antibiotics10020103 · Cited by 24
Kurzyp, K., & Harrison, O. B. (2023) · Microbial Genomics · doi:10.1099/mgen.0.001040 · Cited by 24
Cardenas, A. J., Thomas, K. S., Broden, M. W., Ferraro, N. J., John, C. M., Pires, M. M., Jarvis, G. A., & Criss, A. K. (2024) · mBio · doi:10.1128/mbio.00119-24 · Cited by 21
Efficacy of Antigonococcal CMP-Nonulosonate Therapeutics Require Cathelicidins
Gulati, S., Schoenhofen, I. C., Lindhout, T., Lewis, L. A., Moustafa, I. Y., Saha, S., Zheng, B., Nowak, N., Rice, P. A., Varki, A. P., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa438 · Cited by 16
Self-citationAn optimized Factor H-Fc fusion protein against multidrug-resistant Neisseria gonorrhoeae
Shaughnessy, J., Chabeda, A., Tran, T. H. Y., Zheng, B., Nowak, N., Steffens, C., DeOliveira, R. B., Gulati, S., Lewis, L. A., Maclean, J. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975676 · Cited by 15
Self-citationTherapeutic CMP-Nonulosonates against Multidrug-Resistant Neisseria gonorrhoeae
Gulati, S., Schoenhofen, I. C., Lindhout, T., Schur, M. J., Landig, C. S., Saha, S., Deng, L., Lewis, L. A., Zheng, B., Varki, A. P., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901398 · Cited by 13
Self-citationShaughnessy, J., Tran, T. H. Y., Zheng, B., DeOliveira, R. B., Gulati, S., Song, W., Maclean, J. M., Wycoff, K. L., & Ram, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583305 · Cited by 12
Self-citationChakraborti, S., Gulati, S., Zheng, B., Beurskens, F. J. M., Schuurman, J., Rice, P. A., & Ram, S. (2019) · Infection and Immunity · doi:10.1128/iai.00862-19 · Cited by 8
Self-citationMoulding, P. B., & El-Halfawy, O. M. (2024) · Canadian Journal of Microbiology · doi:10.1139/cjm-2024-0017 · Cited by 8
Comparison of lipooligosaccharides from human challenge strains of Neisseria gonorrhoeae
John, C. M., Phillips, N. J., Cardenas, A. J., Criss, A. K., & Jarvis, G. A. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1215946 · Cited by 6
Preventing human influenza and coronaviral mono or coinfection by blocking virus-induced sialylation
Amin, M. R., Anwar, K. N., Ashraf, M. J., Ghassemi, M., & Novak, R. M. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.106041 · Cited by 5
Kurt‐Jones, E. A., Gulati, S., King, M., DeOliveira, R. B., Rice, P. A., Zheng, B., Shaughnessy, J., Edwards, J. L., Hertzog, P. J., Ram, S., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.05.015 · Cited by 5
Self-citationJohn, C. M., Otala, S. A., & Jarvis, G. A. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00997-24 · Cited by 4
Dijokaite-Guraliuc, A., Humbert, M. V., Skipp, P. J. S., Cleary, D. W., Heckels, J. E., & Christodoulides, M. (2023) · Frontiers in Bacteriology · doi:10.3389/fbrio.2023.1240807 · Cited by 6
Sialic Acid-Binding Ig-Like Lectins (Siglecs)
Kim, C. (2022) · Springer eBooks · doi:10.1007/978-981-16-9081-5_7 · Cited by 3
Bacterial post-translational changes: the possible enigma of multidrug resistance
Sahana, M., Gadilingappa, M. N., & Bhat, G. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04754-4 · Cited by 1
Dissecting the intestinal mucosal niche with the pathobiont Allobaculum mucolyticum
van Muijlwijk, G. H. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1173 · Cited by 1
Bacterial Lipopolysaccharide-Dependent Complement Evasion
Futoma-Kołoch, B. (2017)
Pathogenicity and virulence of Neisseria gonorrhoeae
Girgis, M. M. K., & Christodoulides, M. (2026) · Virulence · doi:10.1080/21505594.2026.2749908
Metadata
- Authors
- Lewis, L. A., Gulati, S., Burrowes, E., Zheng, B., Ram, S., & Rice, P. A.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Lewis, Lisa A.
- Venue
- mBio
- Publisher
- American Society for Microbiology
- Published
- 2015-02-27
- Volume
- 6
- Issue
- 1
- ISSN
- 2150-7511 (ISSN-L)
- 2161-2129
- PMC
- PMC4324315
- OpenAlex
- W2103237266
- Cited by
- 43
- References
- 57
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 3 · 2019: 5 · 2018: 5 · 2017: 3 · 2016: 6 · 2015: 1
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- mBio (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Centers for Disease Control and Prevention
- National Institute of Allergy and Infectious Diseases (AI084048, R01AI032725, AI 054544, R37AI032725, R56AI032725, AI32725, R01AI054544, U19AI084048)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- Neisseria meningitidis, alpha2,3-sialyltransferase, land surface temperature, sialic acid, complement resistance, complement factor H, lacto-N-neotetraose, genital tract colonization, co-infection
- MeSH terms
- Animals, Bacterial Proteins, Complement System Proteins, Female, Genitalia, Female, Gonorrhea, Humans, Kinetics, Lipopolysaccharides, Neisseria gonorrhoeae, Sialic Acids, Sialyltransferases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.